May 6 2024 |
et al., Advances in Respiratory Medicine, doi:10.3390/arm92030021 | RNA Polymerase Inhibitor Enisamium for Treatment of Moderate COVID-19 Patients: A Randomized, Placebo-Controlled, Multicenter, Double-Blind Phase 3 Clinical Trial |
| no change in recovery, 86% lower mortality (p=0.25), 75% lower progression (p=0.03), and 9% faster improvement (p=0.01). RCT 592 hospitalized moderate COVID-19 patients in Ukraine showing improved recovery and lower progression with enisamium. The trial initially included patients with moderate COVID-19 not requiring oxygen, but a mid-trial change was made .. | ||
Sep 17 2021 |
et al., Biomedicines, doi:10.3390/biomedicines9091254 | Enisamium Inhibits SARS-CoV-2 RNA Synthesis |
| In vitro study showing inhibition of SARS-CoV-2 RNA synthesis by enisamium and its metabolite VR17-04. Authors showed that enisamium inhibited SARS-CoV-2 infection in Caco-2 cells with an IC50 of 1.2 mM and coronavirus HCoV-NL63 infection.. | ||
Please send us corrections, updates, or comments.
c19early involves the extraction of 100,000+ datapoints from
thousands of papers. Community updates
help ensure high accuracy.
Treatments and other interventions are complementary.
All practical, effective, and safe
means should be used based on risk/benefit analysis.
No treatment or intervention is 100% available and effective for all current
and future variants.
We do not provide medical advice. Before taking any medication,
consult a qualified physician who can provide personalized advice and details
of risks and benefits based on your medical history and situation. IMA and WCH
provide treatment protocols.
Thanks for your feedback! Please search before submitting papers and note
that studies are listed under the date they were first available, which may be
the date of an earlier preprint.